Advantages and drawbacks of cytometry techniques. This table lists the most representative advantages and disadvantages of the different immunophenotyping procedures, as well as some references that collect applications of these techniques in DILI research
Immunophenotyping techniques | Description and applications | Advantages | Drawbacks | Applications in DILI research |
---|---|---|---|---|
IFC | IFC platform combines features of flow cytometry and fluorescent microscopy with data-processing algorithms, allowing for the evaluation of morphological and fluorescent data and analysing protein expression in single cells in heterogeneous cell populations |
|
| [29] |
Multicolor flow cytometry | Technology that uses multiple fluorescent markers to identify and characterize cellular subpopulations of interest with the possibility of isolating pure, viable populations by cell sorting |
|
| [30–33] |
Mass cytometry | Mass cytometry utilizes elemental mass spectrometry to detect metal-conjugated antibodies bound intracellularly or extracellularly to antigens of interest on single cells, allowing the simultaneous analysis of a great number of cellular features |
|
| [33–35] |
Hyperspectral flow cytometry | Single-cell analysis technique that combines ultrafast optical spectroscopy and flow cytometry. This technology uses diffraction gratings or prism-based monochromators to disperse fluorescence signals from multiple labels onto linear detector arrays |
|
| No data |
ACS: Writing—original draft. DEDZS: Writing—original draft, Writing—review & editing. ASZ, GMC, and ABG: Writing—review & editing. MIL: Conceptualization, Writing—review & editing, Supervision. MVP: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. All authors contributed to the manuscript revision, and read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This work was supported by grants from the Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional (FEDER), contract numbers: [PI21/01248], [PI19-00883], [PT 20/00127], [UMA18-FEDERJA-194], [PY18-3364]; and grants from Consejería de Salud de Andalucía cofounded by FEDER, contract number: [PEMP-0127-2020]. Marina Villanueva-Paz holds a Sara Borrell [CD21/00198] research contract from Instituto de Salud Carlos III (ISCIII) and Consejería de Salud de Andalucía. Alejandro Cueto-Sánchez holds an i-PFIS: Doctorados IIS-empresa en Ciencias y Tecnologías de la Salud [IFI18/00047] research contract from ISCIII. Daniel E. Di Zeo-Sánchez holds an i-PFIS: Doctorados IIS-empresa en Ciencias y Tecnologías de la Salud [IFI21/00034] research contract from ISCIII. Gonzalo Matilla-Cabello holds a Garantía Juvenil [SNGJ5Y6-09] research contract with Junta de Andalucía and the European Social Fund. Antonio Segovia-Zafra holds a Jaume Bosch Training Action 2022 from Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD). Ana Bodoque-García holds a Garantía Juvenil [POEJ-00041-IBIMA] research contract from Junta de Andalucía and the European Social Fund. Spanish Clinical Research Network (SCReN) and CIBEREHD are funded by ISCIII. This publication is based on work from COST Action ‘CA17112—Prospective European Drug-Induced Liver Injury Network’ supported by COST (European Cooperation in Science and Technology), www.cost.eu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.